Pioneering a treatment for Alzheimer’s disease

Breaking boundaries in the research, diagnosis and treatment of dementia

Plexus lines and dots forming a human brain

2 Asian mature businessmen discussion performance review business plan in office

Investors

A unique opportunity in an untapped, multi-billion-dollar global market

Home doctor is visiting senior man to check his health. Professional caregiver is assisting old man at his home.

Patients and carers

Our mission is to make a positive difference to the lives of the individuals, carers and families affected by neurodegenerative diseases

A female doctor sits across her desk from a senior patient as she discusses her recent test results. She is wearing a white lab coat and has a tablet out on the desk in front of the two as they discuss the results.

Medical professionals

Empowering clinicians with pioneering research and treatment insights

Working to develop a treatment for one of the world’s greatest unmet medical needs

Medical Research Center: Close Up Portrait Of Caucasian Male Neurologist, Neuroscientist, Neurosurgeon, Looks at TV Screen with Brain MRI Scan Images

55 million

People living with dementia worldwide

10 million

New cases globally every year

$1.3 trillion

Estimated global cost of dementia in 2019 (USD)

*Latest available statistics from the World Health Organization

Where we are today
The TauRx story so far

1988
1996
2002
2004
2012
2015
2017
2019
2020
2021
2022
2024

1988

Claude Wischik discovers structure of tau tangles.
1996

Wischik discovers tau tangles can be dissolved by methylthionimium class molecules. He and his team publish first report on Tau Aggregation Inhibitors (TAI).
2002

TauRx founded in Singapore.
2001-2008

First phase II trial of Tau Aggregation Inhibitor (TAI).
2012-2016

First phase III trials in mild-moderate AD and frontotemporal dementia.
2015

Phase II trial results.
2017-2018

Phase III trial results.
2019

Phase III trial results in Alzheimer's disease (AD) and frontotemporal dementia show pharmacological activity on clinical decline and brain atrophy.
2020

LUCIDITY trials begin in North America and Europe.
2021

Tau Aggregation Inhibitor (TAI) enhances neuron communication in mice.
2022

Top line results from the LUCIDITY clinical trials lead to first Tau Aggregation Inhibitor (TAI).
2024

We have submitted our first product, HMTM, for approval to the Medicines and Healthcare products Regulatory Agency (MHRA) as a tablet to treat MCI and mild to moderate Alzheimer's disease.

1988

1996

2002

2001-2008

2012-2016

2015

2017-2018

2019

2020

2021

2022

2024

The latest from TauRx

30 July 2024

MHRA confirms acceptance of UK Marketing Authorisation Application for HMTM

1 July 2024

TauRx submits UK marketing authorisation application for HMTM as a treatment for Alzheimer’s disease

Doctor examining MRI, MRT, CT scan image of human brain. Medical treatment concept. Diagnosis of the disease humans head. Close up.

7 March 2024

Two year sustained cognitive benefits of Hydromethylthionine Mesylate (HMTM) indicated by TauRx’s LUCIDITY trial

All news

Conceptual illustration of neuron cells with glowing link knots in abstract dark space, high resolution 3D illustration

Provide hope for millions

Join us in changing the course of Alzheimer’s disease

For most people living with Alzheimer's - the most common form of dementia - their only option is long-term care to manage their symptoms. Following three decades of research, we are ready to commercialise what we believe is an effective treatment to change this prognosis, to give patients and their families a completely different future.

Find out more